Neoadjuvant Endocrine Therapy for Strongly HR-Positive and HER2-Negative Early Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Neoadjuvant endocrine therapy for strongly hormone receptor-positive and HER2-negative early breast cancer: results of a prospective multi-center study
Breast Cancer Res Treat 2022 Aug 02;[EPub Ahead of Print], X Wang, Z Fan, X Wang, Y He, Y Liu, X Wang, B Zhang, Z Jiang, T Wang, Z Yu, F Wang, Y Liu, Y Li, J Zhang, B Luo, H Jiang, T Wang, Y Xie, J Li, T OuyangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.